JP Morgan Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
JP Morgan has maintained its Neutral rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) and increased its price target from $28.00 to $29.00. ACADIA's shares are currently trading down 1.51% at $26.78 per share. A move to $29.00 would represent an 8.29% increase from the current share price.
August 07, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan has maintained its Neutral rating for ACADIA Pharmaceuticals and raised its price target. This could potentially lead to an increase in the stock's price if the market aligns with JP Morgan's analysis.
The news of JP Morgan maintaining its Neutral rating and raising the price target for ACADIA Pharmaceuticals could potentially impact the stock's price. However, the stock is currently trading down, and the market's reaction to this news is uncertain. Therefore, the score is neutral.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100